<DOC>
	<DOCNO>NCT00521716</DOCNO>
	<brief_summary>The purpose study determine safety efficacy use WaisFix100i device Intracapsular Femoral Fracture Fixation .</brief_summary>
	<brief_title>Safety Efficacy WaisFix100i Intracapsular Femoral Fracture Fixation</brief_title>
	<detailed_description>Fractures neck femur represent estimate cost society exceed ten billion dollar annually USA . Fractures treat immobilization , traction , amputation , internal fixation throughout history . Immobilization casting , bracing , splint joint fracture use long bone fracture . Several study suggest reduction fixation Intracapsular fracture hip multiple pin screw associate low rate morbidity mortality treatment prosthetic replacement . With improved method fixation tendency toward early weight-bearing , internal fixation believe well mode treatment young , active patient . On hand , internal fixation procedure may result number possibility serious complication biomechanical disadvantage , lead device failure . This lead grow tendency prefer total partial hip replacement common treatment intracapsular fracture , although internal fixation favorable procedure professional literature . OrthoMediTec develop WaisFix100i device , new concept Intracapsular Femoral Fracture Fixation bone graft use minimally invasive procedure . The WaisFix100i combine new unique Internal Triangular Cage nail fixator three lag screw . The Internal Triangular Cage insert femoral neck strong , solid beam structure guide hold screws place . The cage supply structure hold bone graft screw fracture site . The objective single arm , multi-center , prospective study , evaluate safety efficacy use WaisFix100i device intracapsular femoral fracture fixation surgery .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Femoral Fractures</mesh_term>
	<criteria>1 . Male/Female Intracapsular femoral fracture type Garden III several III . 2 . Age 50 75 . 3 . Subject able comprehend give inform consent participation study . 1 . Known active infectious disease . 2 . Terminal diseases 3 . Patients high risk and/or acute cardiovascular disease . 4 . Known cognitive disorder , psychiatric and/or neurological disease 5 . Physician objection . 6 . Age 50 75 . 7 . Concurrent participation clinical study 8 . Patients understand willing sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Hip Prosthesis Implantation</keyword>
</DOC>